Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVIg in Early Onset Paraneoplastic Neurological Syndromes
NCT02343211Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2013
- Primary completion
- Jun 2016
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of polyvalent human immunoglobulin in paraneoplastic neurological syndromes (PNS), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Percentage of Patients With Neurological Improvement (Modified Rankin Scale) at 3 months. Started Nov 2013; status: completed.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
paraneoplastic neurological syndromes (PNS)
Beyond the preview
Go deeper on NCT02343211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02343211.